All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

/images/Cortellis_Flagship_Logo_TM_RGB_Color.png
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Artificial intelligence
    • Coronavirus
    • Diagnosing and tracking COVID-19
    • Drugs to Watch 2020
    • The next pandemic
    • Premium reports
      • BioWorld Financings Reports
      • Disease Forecast Reports

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Wednesday, March 3, 2021
Home » Blogs » BioWorld Perspectives

BioWorld Perspectives
BioWorld Perspectives RSS FeedRSS

Old dogs and new tricks: The real-world consequences of excluding older adults from drug trials

Dec. 10, 2014
By Marie Powers
No Comments
How much time do you spend with old people? That’s a loaded question, of course. Age is a relative term, since we age every day and so does the world’s population. Even though the global median age was estimated at a mere 29 years in 2010, the number of people 65 and older is projected to triple by mid-century, from 531 million in 2010 to 1.5 billion in 2050, according to the Pew Research Center. In the U.S., the population of seniors is expected to more than double, from 41 million to 86 million. Still, I spend a lot of time...
Read More

Shoppers, start your engines: BioWorld’s 8th Annual Gift Guide

Dec. 1, 2014
By Marie Powers
No Comments
Google Glass? Fitbit? DNA necktie? Again this year, BioWorld Today polled our staffers, biotech execs, PR folks, tweeps and others in the science world to bring our readers top finds for the holidays. Enjoy! Books and entertainment             In February, the FDA met to consider whether and how to conduct trials to test gene manipulation techniques to prevent mitochondrial disease from occurring in offspring. “Are we heading to a world envisaged in Gattaca?” asked BioWorld Insight Editor Peter Winter, suggesting it might be time to substitute the 1997 movie for the even older holiday classic, Miracle on 34th Street. (Just...
Read More

Death and taxes: Is the corporate tax rate killing the U.S. economy?

Oct. 23, 2014
By Ann Duncan
No Comments
“In this world nothing can be said to be certain, except death and taxes.” Benjamin Franklin “The only difference between death and taxes is that death doesn't get worse every time Congress meets.” Will Rogers The IRS and the U.S. Treasury last month announced plans to squelch the trend for businesses to seek foreign tax shelters through corporate inversions. But why are companies fleeing? Because the current corporate tax rate is oppressive. (See BioWorld Today, Sept. 24, 2014.) It’s time to change the U.S. tax code, starting with the corporate tax rate. In an article from the political website Red...
Read More

A shot in the dark? ‘Flu’ Manchu-type fears of evil pharma, plus frets over strains and safety, keep too many away from vaccine

Oct. 7, 2014
By Randy Osborne
No Comments
By now I’ve learned to keep my flu shot habit a secret. Every year about this time, since I was 18 years old, I get vaccinated. But long ago I stopped telling people about it, so I don’t have to hear: “Oh, you know the flu vaccines are made of antifreeze [mercury, aluminum, formaldehyde], right?” or “That’s a crazy thing to do, because the shot itself can make you sick!” or – this one’s fairly new – “You don’t really need it if you’ve got a healthy immune system. Anyway flu shots cause Alzheimer’s [in the old] and autism [in...
Read More

Emerging biosimilar market knows no parallel

Sep. 29, 2014
By Mari Serebrov
No Comments
It’s not every day that drugmakers get a chance to take on an entirely new market. Biosimilars are offering that opportunity. And hundreds of drugmakers, research institutions and governments are hoping to make the most of it. The result is more than 700 follow-on biologics (FOBs) already approved or in the global pipeline, according to a new report by BioWorld. Those entering the field are as diverse as the FOBs they’re developing. Biologics pioneers, big pharma and generic drugmakers are being joined by “pure-play” start-ups, conglomerates, public-private consortia, contract manufacturers, contract research organizations, government agencies, nonprofits and research institutions. Some...
Read More

Ebola is raging like a wildfire

Sep. 18, 2014
By Mari Serebrov
No Comments
Testifying in a joint Senate committee hearing on Ebola this week, the CDC’s Beth Bell compared the epidemic spreading through West Africa with a forest fire. She stressed that any ember left undetected could quickly flare up and re-ignite the conflagration. Her analogy took me back more than 25 years to my time as a news director for a radio station in Idaho. It was the summer of 1988, and Yellowstone National Park was on fire. The park neighbored the county where I lived, and the smoke from the fires formed a dense fog that blocked the sun for several...
Read More

Balancing innovation and access: The policy conundrum

Sep. 15, 2014
By Jennifer Boggs
No Comments
RIO DE JANEIRO – I was in college when I first read Ayn Rand’s Atlas Shrugged. Safe within the privileged and idealistic bubble of academia, I found myself agreeing with Rand at every turn, filled with the pro-capitalist and individualist spirit.  Why should those who work hard and are successful not be suitably rewarded for their efforts? For government to step in and limit those rewards was unfair and high-handed, socialistic even. I mean, the horror. (Did I mention I was in college?) Fast forward a few years.  I was out of college and working – paying my dues as...
Read More

A little irony here? FDA’s technical difficulties on social media webinar send folks a’Twitter’

July 10, 2014
By Marie Powers
No Comments
For more than five years, the FDA was criticized for failing to provide clear guidance on how drug developers could use social media without running afoul of its marketing restrictions. Last month, the agency finally came through with two crucial draft guidances. A webinar Thursday afternoon aimed at providing more color around the social media regulatory framework could only be described as an #EPICFAIL. The webinar, for which registration reportedly closed early due to overwhelming demand, suffered problems from the get-go, with many registrants unable to log in at all. Almost immediately, slides started crashing, prompting the agency to pause...
Read More

Old news, yet still making headlines

June 13, 2014
By Mari Serebrov
No Comments
High drug prices are old news. Old, as in 19th century old. But that doesn’t mean they aren’t breaking news today. Breaking, as in breaking the family budget. One of the speakers at the Institute of Medicines National Cancer Policy Forum flipped through slide after slide of newspaper headlines screaming about high drug prices. The headlines were from every decade stretching back into the 1800s. Yet today’s headlines report what some have called “pornographic drug prices” as breaking news. What’s new is that drugs are now available for many more diseases that once had no treatment options. And those drugs...
Read More

Pigoons, politicians and the periodic table: BioWorld’s 8th annual biotech summer reading list

June 6, 2014
By Marie Powers
No Comments
Ah, the summer holidays. Time to unplug – for minutes, hours or days at a time – prop up your feet and kick back. But what about a good read? Should you grab a relaxing snoozer that won’t tax your brain or a thriller that will keep you on the edge of your seat? A topic that relates to the biotech field or a subject as far removed from the office as possible? History or science fiction? Inspiration or cautionary tale? Whatever your preference, BioWorld has options. One respondent to the survey for our 2014 reading list, the 8th in...
Read More
Previous 1 2 3 4 5 6 7 8 9 10 … 22 23 Next

Popular Stories

  • Free access to BioWorld coronavirus articles

    BioWorld

    The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus outbreak. Note that we have added three critical tables which are...

  • Today's news in brief

    BioWorld
    BioWorld briefs for March 2.
  • Gloved hand places sample tubes in PCR system

    COVID-19 test makers are adapting for variants

    BioWorld MedTech
    As COVID-19 variants have emerged, so have questions about the effectiveness of tests for infection. While the risk of mutations significantly limiting their...
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech's briefs for March 2.
  • Celltrion-Regkirona-2-9

    Celltrion wins first conditional Korean approval for COVID-19 antibody Regkirona

    BioWorld
    HONG KONG – Celltrion Inc. has received conditional marketing authorization from the Ministry of Food and Drug Safety (MFDS) for its anti-COVID-19 monoclonal...
cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • About
    • Archives
    • Today's news
    • Search BioWorld Science
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
A Clarivate Analytic solution. Link to Clarivate website.
Follow Us

Copyright ©2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing